(Press-News.org) LA JOLLA, CALIF. - May 19, 2021 - A study led by scientists at Sanford Burnham Prebys Medical Discovery Institute has identified a tumor marker that may be used to predict which breast cancer patients will experience resistance to endocrine therapy. The research offers a new approach to selecting patients for therapy that targets HER2, a protein that promotes the growth of cancer cells, to help avoid disease relapse or progression of endocrine-sensitive disease.
The study was published in the journal Nature Communications.
Nearly 80% of breast tumors are estrogen receptor (ER)-positive. For decades, these tumors have been treated with anti-estrogen (endocrine) therapies to lower estrogen levels and help slow the cancer's growth. About 20% of breast cancers are also HER2-positive at diagnosis, and these tumors tend to be more aggressive and fast-growing, as HER2 is a receptor that when active, promotes the rapid growth of breast cancer cells.
"We know there is a subset of patients who are initially diagnosed with ER-positive, HER2-negative breast tumors, but their tumors convert to HER2-positive after they receive endocrine therapy," says Svasti Haricharan, Ph.D., assistant professor in the Aging, Cancer and Immuno-oncology Program at Sanford Burnham Prebys and senior author of the study. "Unfortunately, this unleashes the detrimental effects of HER2, and patients become resistant to endocrine therapy--resulting in relapse, metastasis and death."
With conventional endocrine therapy being unhelpful for these patients, Haricharan's team examined how two genes, MLH1 and PMS2, affect HER2 activity. These genes are part of a biological system to "fix" DNA errors--but they also play a critical role in suppressing HER2. When these genes are turned off, HER2 becomes activated as soon as patients receive standard care endocrine therapy.
"Fortunately, there are tests for MLH1 and PMS2 activity that are now done routinely for colorectal and endometrial cancers," says Nindo Punturi, a research assistant in the Haricharan lab and first author of the paper. "If we were to transition these tests to newly diagnosed cases of breast cancer, we could identify patients who may benefit from early HER2 targeted treatment--essentially shutting the door to HER2 activity before it gets started."
The National Cancer Institute (NCI) estimates that 281,550 women in the U.S. will be diagnosed with breast cancer in 2021, and 43,600 women will eventually die from the disease. Some women whose MLH1 and PMS2 gene expression is low or absent may have an even greater risk of death.
"Our research efforts are all about getting the right treatments to the right people as soon as possible," says Haricharan. "With so many excellent drugs at our disposal to treat breast cancer--including those that target HER2--it's more a matter of selecting the available, appropriate drugs than searching for new ones. This research effort is an important step in that direction."
INFORMATION:
Additional study authors include Nindo B. Punturi, Sinem Seker and Aloran Mazumder at Sanford Burnham Prebys; Vaishnavi Devarakonda, Rashi Kalra, Ching-Hui Chen, Matthew J. Ellis and Shyam M. Kavuri at Baylor College of Medicine in Houston; and Shunqiang Li and Tina Primeau at Washington University in St. Louis.
The study's DOI is 10.1038/s41467-021-23271-0.
Research reported in this press release was supported by Department of Defense (DoD) Breast Cancer Research Program Breakthrough awards (W81XWH-18-1-0034 to SH, W81XWH-18-1-36 0035 to SMK), an NCI K22 Career Development award (CA229613 to SH), a Susan G. Komen Promise grant (PG12220321 to MJE), a Cancer Prevention and Research Institute of Texas Recruitment of Established Investigators award (RR140033 to Matthew J. Ellis), and NCI awards U10CA180821, U10CA180882 (to the Alliance for Clinical Trials in Oncology) and U24C196171.
The authors declare these competing interests: Matthew J. Ellis has intellectual property ownership and received royalties for the PAM50-based breast cancer test Prosigna. Over the last five years he has received ad hoc consulting fees and meals (less than $5,000 per year) from Abbvie, Novartis, AstraZeneca, Pfizer, Sermonix and Puma. Shyam M. Kavuri is a stakeholder in NeoZenome Therapeutics Inc. Shunqiang Li has received license fees from Envigo; as well as research funding from Pfizer, Takeda Oncology, Zenopharm, the National Institutes of Health, and the DoD outside of this project.
About Sanford Burnham Prebys Medical Research Institute
Sanford Burnham Prebys is a preeminent, independent biomedical research institute dedicated to understanding human biology and disease and advancing scientific discoveries to profoundly impact human health. For more than 40 years, our research has produced breakthroughs in cancer, neuroscience, immunology and children's diseases, and is anchored by our NCI-designated Cancer Center and advanced drug discovery capabilities. For more information, visit us at SBPdiscovery.org or on Facebook at facebook.com/SBPdiscovery and on Twitter @SBPdiscovery.
Turns out the old adage, "monkey see, monkey do," does ring true -- even when it comes to cannabis use. However, when cannabis use involves youth it's see, think, then do, says a team of UBC Okanagan researchers.
The team found that kids who grow up in homes where parents consume cannabis will more than likely use it themselves. Parental influence on the use of cannabis is important to study as it can help with the development of effective prevention programs, explains Maya Pilin, a doctoral psychology student in the Irving K. Barber Faculty of Arts and Social Sciences.
"Adolescence is a critical period in which drug and alcohol experimentation takes place and when cannabis use is often initiated," says Pilin. "Parents are perhaps the most influential socializing agent for ...
People with bipolar disorder may not take their medication because of side effects, fear of addiction and a preference for alternative treatment - according to research from Norfolk and Suffolk NHS Foundation Trust (NSFT) and the University of East Anglia (UEA).
Nearly half of people with bipolar disorder do not take their medication as prescribed leading to relapse, hospitalisation, and increased risk of suicide.
A new study, published today, reveals six key factors that stop people taking their medication as prescribed.
These include whether they are experiencing side effects, difficulties in remembering to take medication and a lack of support from family, friends and healthcare ...
Researchers at the University of Eastern Finland have found a potential neuroprotective effect of a protein modification that could be a therapeutic target in early Alzheimer's disease. The new study investigated the role of MECP2, a regulator of gene expression, in Alzheimer's disease related processes in brain cells. The study found that phosphorylation of MECP2 protein at a specific amino acid decreases in the brain as Alzheimer's disease is progressing. Abolishing this phosphorylation of MECP2 in cultured mouse neurons upon inflammatory stimulation enhanced their viability and ...
A study led by MedUni Vienna (Institute of Cancer Research and Comprehensive Cancer Center Vienna) sheds light on the mechanisms that lead to extremely aggressive metastasis in a particular type of pancreatic cancer, the basal subtype of ductal adenocarcinoma. The results contribute to a better understanding of the disease. The study has recently been published in the leading journal "Gut".
The most prevalent form of pancreatic cancer, Pancreatic Ductal AdenoCarcinoma (PDAC) is usually divided into two subtypes, a classical subtype and a basal subtype. The latter is highly aggressive and tends towards early metastasis. One of the distinguishing features between the two subtypes is that the classical subtype exhibits the protein GATA6. This is no longer present ...
Water in the high-mountain regions has many faces. Frozen in the ground, it is like a cement foundation that keeps slopes stable. Glacial ice and snow supply the rivers and thus the foothills with water for drinking and agriculture during the melt season. Intense downpours with flash floods and landslides, on the other hand, pose a life-threatening risk to people in the valleys. The subsoil with its ability to store water therefore plays an existential role in mountainous regions.
But how can we determine how empty or full the soil reservoir is in areas that are difficult to access? Researchers at the German Research Centre for Geosciences (GFZ), together with colleagues from Nepal, have now demonstrated an elegant method to track groundwater dynamics in high ...
The latest findings show that with clever science, a single fingerprint left at a crime scene could be used to determine whether someone has touched or ingested class A drugs.
In a paper published in Royal Society of Chemistry's Analyst journal, a team of researchers at the University of Surrey, in collaboration with the National Centre of Excellence in Mass Spectrometry Imaging at the National Physical Laboratory (NPL) and Ionoptika Ltd reveal how they have been able to identify the differences between the fingerprints of people who touched cocaine compared with those who have ingested the drug - even if the hands are not washed. The smart science behind the advance is the mass spectrometry imaging tools applied to the detection of cocaine ...
Problems for eigenmodes of a two-layered dielectric microcavity have become widespread thanks to the research of A.I. Nosich, E.I. Smotrova, S.V. Boriskina and others since the beginning of the 21st century. The KFU team first tackled this topic in 2014; undergraduates started working under the guidance of Evgeny Karchevsky, Professor of the Department of Applied Mathematics of the Institute of Computational Mathematics and Information Technology.
In this paper, the researchers discuss a model of a 2D active microcavity with a piercing hole and the possibility of a compromise between high directionality of radiation ...
The last ice age ended almost 12 000 years ago in Norway. The land rebounded slowly as the weight of the ice disappeared and the land uplift caused many bays to become narrower and form lakes.
Fish became trapped in these lakes.
Sticklebacks managed to adapt when saltwater became freshwater, and they can still be found in today's coastal lakes along the Norwegian coast.
Saltwater gradually changed to brackish water and later to freshwater. This environmental change naturally led to a total replacement of the animal and plant life.
The exception is the tiny stickleback, which successfully adapted as saltwater became freshwater and ...
A reason for these findings could be due to the fact that Parkinson's patients often also have many risk factors for a severe course of Covid-19. For the first time, the cross-sectional study provides detailed nationwide data. The research team led by Professor Lars Tönges reports in the journal Movement Disorders of 4 May 2021.
Nationwide analysis of hospital data
The team headed by Lars Tönges has analysed data on Parkinson's treatment in 1,468 hospitals. The data were taken from nationwide databases in which information on the treated diseases and of treatments carried out in hospitals is publicly collected, for example by the Institute for the Hospital Remuneration System or the Federal Statistical Office.
A comparison between the period of the first ...
Blocked blood vessels in the brains of stroke patients prevent oxygen-rich blood from getting to cells, causing severe damage. Plants and some microbes produce oxygen through photosynthesis. What if there was a way to make photosynthesis happen in the brains of patients? Now, researchers reporting in ACS' Nano Letters have done just that in cells and in mice, using blue-green algae and special nanoparticles, in a proof-of-concept demonstration.
Strokes result in the deaths of 5 million people worldwide every year, according to the World Health Organization. Millions more survive, but they often experience disabilities, such as difficulties with speech, swallowing or memory. The most common cause is a blood vessel blockage in the brain, and the best way to ...
